Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins

Antiviral Research

Volumn 111, Issue , 2014, Pages 129-135

  Lee, Sujin ^a,b   Quan, Fu Shi ^a,c   Kwon, Youngman ^d   Sakamoto, Kaori ^e   Kang, Sang Moo ^d   Compans, Richard W ^a   Moore, Martin L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c Kyung Hee University Hospital   (South Korea)

^d GEORGIA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

Author keywords

Lung pathology; Respiratory syncytial virus; RSV attachment glyco (G) protein; RSV fusion (F) protein; Virus like particle (VLP)

Indexed keywords

GLYCOPROTEIN; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LOWER RESPIRATORY TRACT; MOUSE; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TH1 CELL; VACCINATION; VIRUS ATTACHMENT; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

EID: 84908007666     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.09.005     Document Type: Article

References (33)

1. A. Cherukuri, K.L. Stokes, K. Patton, H. Kuo, K. Sakamoto, S. Lambert, E. Stillman, M.L. Moore, and S. Lee An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice Immun. Ageing 9 2012 21
2. L. de Waal, U.F. Power, S. Yuksel, G. van Amerongen, T.N. Nguyen, H.G. Niesters, R.L. de Swart, and A.D. Osterhaus Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge Vaccine 22 2004 915 922
3. M.F. Delgado, S. Coviello, A.C. Monsalvo, G.A. Melendi, J.Z. Hernandez, J.P. Batalle, L. Diaz, A. Trento, H.Y. Chang, W. Mitzner, J. Ravetch, J.A. Melero, P.M. Irusta, and F.P. Polack Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease Nat. Med. 15 2009 34 41
4. B.S. Graham Biological challenges and technological opportunities for respiratory syncytial virus vaccine development Immunol. Rev. 239 2011 149 166
5. F. Hesse, and R. Wagner Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures Trends Biotechnol. 18 2000 173 180
6. A.L. Hotard, F.Y. Shaikh, S. Lee, D. Yan, M.N. Teng, R.K. Plemper, J.E. Crowe Jr., and M.L. Moore A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis Virology 434 2012 129 136
7. J.E. Johnson, R.A. Gonzales, S.J. Olson, P.F. Wright, and B.S. Graham The histopathology of fatal untreated human respiratory syncytial virus infection Mod. Pathol. 20 2007 108 119
8. T.R. Johnson, and B.S. Graham Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection Pediatr. Infect. Dis. J. 23 2004 S46 57
9. A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, and C.E. Stewart An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Am. J. Epidemiol. 89 1969 405 421
10. + T cell responses in aged mice J. Immunol. 192 2014 293 299
11. + T cells protect against respiratory syncytial virus strain A2-Line19F-induced pathogenesis in BALB/c mice J. Virol. 86 2012 13016 13024
12. M. Magro, V. Mas, K. Chappell, M. Vazquez, O. Cano, D. Luque, M.C. Terron, J.A. Melero, and C. Palomo Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention Proc. Natl. Acad. Sci. U.S.A. 109 2012 3089 3094
13. L.W. McGinnes, K.A. Gravel, R.W. Finberg, E.A. Kurt-Jones, M.J. Massare, G. Smith, M.R. Schmidt, and T.G. Morrison Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins J. Virol. 85 2011 366 377
14. J.S. McLellan, M. Chen, S. Leung, K.W. Graepel, X. Du, Y. Yang, T. Zhou, U. Baxa, E. Yasuda, T. Beaumont, A. Kumar, K. Modjarrad, Z. Zheng, M. Zhao, N. Xia, P.D. Kwong, and B.S. Graham Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody Science 340 2013 1113 1117
15. A. Monie, C.F. Hung, R. Roden, and T.C. Wu Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer Biologics 2 2008 97 105
16. M.L. Moore, M.H. Chi, C. Luongo, N.W. Lukacs, V.V. Polosukhin, M.M. Huckabee, D.C. Newcomb, U.J. Buchholz, J.E. Crowe Jr., K. Goleniewska, J.V. Williams, P.L. Collins, and R.S. Peebles Jr. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction J. Virol. 83 2009 4185 4194
17. E.O. Ohuma, E.A. Okiro, R. Ochola, C.J. Sande, P.A. Cane, G.F. Medley, C. Bottomley, and D.J. Nokes The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease Am. J. Epidemiol. 176 2012 794 802
18. R.A. Olmsted, N. Elango, G.A. Prince, B.R. Murphy, P.R. Johnson, B. Moss, R.M. Chanock, and P.L. Collins Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity Proc. Natl. Acad. Sci. U.S.A. 83 1986 7462 7466
19. M.R. Olson, S.M. Hartwig, and S.M. Varga The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia J. Immunol. 181 2008 7958 7968
20. M.R. Olson, and S.M. Varga CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease J. Immunol. 179 2007 5415 5424
21. R.S. Peebles Jr., J.R. Sheller, R.D. Collins, K. Jarzecka, D.B. Mitchell, and B.S. Graham Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV J. Infect. Dis. 182 2000 671 677
22. F.S. Quan, C. Huang, R.W. Compans, and S.M. Kang Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus J. Virol. 81 2007 3514 3524
23. F.S. Quan, Y. Kim, S. Lee, H. Yi, S.M. Kang, J. Bozja, M.L. Moore, and R.W. Compans Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice J. Infect. Dis. 204 2011 987 995
24. M.R. Schmidt, L.W. McGinnes, S.A. Kenward, K.N. Willems, R.T. Woodland, and T.G. Morrison Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains J. Virol. 86 2012 11654 11662
25. K. Schneider-Ohrum, and T.M. Ross Virus-like particles for antigen delivery at mucosal surfaces Curr. Top. Microbiol. Immunol. 354 2012 53 73
26. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection J. Exp. Med. 186 1997 421 432
27. A. Srikiatkhachorn, and T.J. Braciale Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection J. Virol. 71 1997 678 685
28. K.L. Stokes, M.H. Chi, K. Sakamoto, D.C. Newcomb, M.G. Currier, M.M. Huckabee, S. Lee, K. Goleniewska, C. Pretto, J.V. Williams, A. Hotard, T.P. Sherrill, R.S. Peebles Jr., and M.L. Moore Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice J. Virol. 85 2011 5782 5793
29. J.J. Treanor, H. El Sahly, J. King, I. Graham, R. Izikson, R. Kohberger, P. Patriarca, and M. Cox Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial Vaccine 29 2011 7733 7739
30. S.M. Varga, X. Wang, R.M. Welsh, and T.J. Braciale Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells Immunity 15 2001 637 646
31. T. Vicente, A. Roldao, C. Peixoto, M.J. Carrondo, and P.M. Alves Large-scale production and purification of VLP-based vaccines J. Invertebr. Pathol. 107 Suppl. 2011 S42 48
32. M.E. Waris, C. Tsou, D.D. Erdman, S.R. Zaki, and L.J. Anderson Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern J. Virol. 70 1996 2852 2860
33. H. Zhou, W.W. Thompson, C.G. Viboud, C.M. Ringholz, P.Y. Cheng, C. Steiner, G.R. Abedi, L.J. Anderson, L. Brammer, and D.K. Shay Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008 Clin. Infect. Dis. 54 2012 1427 1436